Gefässchirurgie

, Volume 13, Issue 1, pp 31–41 | Cite as

Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung

Akutmanagement und Sekundärprävention des Schlaganfalls – Teil I
  • J. Willeit
  • S.  Kiechl
  • F. Aichner
  • K. Berek
  • H. Binder
  • M. Brainin
  • F. Fazekas
  • G. Fraedrich
  • H.P. Haring
  • S. Horner
  • B. Iglseder
  • P. Kapeller
  • W. Lang
  • E. Minar
  • K. Niederkorn
  • G. Noisternig
  • M. Schillinger
  • R. Schmidt
  • E. Schmutzhard
  • P. Waldenberger
  • H.W. Wege
Leitlinien
  • 43 Downloads

Zusammenfassung

Der Schlaganfall ist weltweit die dritthäufigste Todesursache und die häufigste Ursache für eine schwere Behinderung im Erwachsenenalter. Jedes Jahr erkranken in Österreich rund 20.000 Menschen daran, etwa 60.000 leiden unter den Schlaganfallfolgen. Neue Erkenntnisse zur Pathophysiologie und Klinik des Schlaganfalls sowie die Einführung moderner diagnostischer Verfahren haben das Management von Schlaganfallpatienten wesentlich geändert.

Basierend auf den aktuellen wissenschaftlichen Erkenntnissen und in der Praxis bewährten Verfahren hat die Österreichische Gesellschaft für Schlaganfallforschung ein Positionspapier zu wichtigen Themenbereichen der Versorgung von Schlaganfallpatienten erarbeitet. Die Daten wurden von Arbeitsgruppen in einem systematischen Review gesammelt und im Expertengremium diskutiert, wobei für die Einstufung in Evidenzgrad und Empfehlungsstärke die EFNS-Kriterien verwendet wurden. Es ist geplant, weitere Themen aufzunehmen und das hier vorgestellte Positionspapier alle zwei Jahre einer Überarbeitung zu unterziehen.

Schlüsselwörter

Schlaganfall Leitlinien Akuttherapie Sekundärprävention EFNS-Kriterien 

Policy document of the Austrian Society of Stroke Research

Acute management and secondary prevention of stroke – Part I

Abstract

Stroke is the third most frequent cause of death in the world overall, and the most common reason for severe disablement in adulthood. Every year, a good 20,000 people in Austria suffer strokes, and about 60,000 suffer from sequelae of strokes. New insights into the pathophysiology and clinical aspects of stroke and the introduction of modern diagnostic techniques have led to substantial changes in the management of stroke patients.

Based on the current scientific knowledge and techniques that have been tried and tested in practice, the Austrian Society of Stroke Research has prepared a position paper on important subject areas in the treatment of stroke patients. The data were collected by working groups in a systematic review and discussed by the expert committee, the EFNS criteria being used for the classification by level of evidence and strength of recommendations. There are plans to pursue new topics, and to review the position paper presented here every two years.

Keywords

Stroke Guidelines Acute management Secondary prevention EFNS criteria 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Hacke W, Donnan G, Fieschi C et al., ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768–774PubMedGoogle Scholar
  2. 2.
    The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group (2000) Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 31: 2912–2919Google Scholar
  3. 3.
    Hill M, Buchan A for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators (2005) Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172: 1307–1312PubMedGoogle Scholar
  4. 4.
    Graham G (2003) Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 34: 2847–2850PubMedGoogle Scholar
  5. 5.
    Wahlgren N, Ahmed N, Dávalos A et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369: 275–282PubMedGoogle Scholar
  6. 6.
    Adams HP, Del Zoppo G, Alberts MJ et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655–1711PubMedGoogle Scholar
  7. 7.
    Kohrmann MJ, Juttler E, Fiebach J et al. (2006) MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 5: 661–667PubMedGoogle Scholar
  8. 8.
    Külkens S, Ringleb P, Hacke W (2004) Empfehlungen der European Stroke Initiative (EUSI) zur Behandlung des ischämischen Schlaganfalls – Aktualisierung 2003. Nervenarzt 75: 368–379PubMedGoogle Scholar
  9. 9.
    Zangerle A, Kiechl S, Spiegel M et al. (2007) Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 68: 39–44PubMedGoogle Scholar
  10. 10.
    del Zoppo G, Higashida R, Furlan A et al. (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29: 4–11Google Scholar
  11. 11.
    Alexandrov A, Molina C, Grotta J et al., CLOTBUST Investigators (2004) Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351: 2170–2178PubMedGoogle Scholar
  12. 12.
    Daffertshofer M, Gass A, Ringleb P et al. (2005) Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 36: 1441–1446PubMedGoogle Scholar
  13. 13.
    Smith W (2006) Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 27: 1177–1182PubMedGoogle Scholar
  14. 14.
    Gralla J, Schroth G, Remonda L et al. (2006) Mechanical thrombectomy for acute ischemic stroke: thrombus-device interaction, efficiency, and complications in vivo. Stroke 37: 3019–3024PubMedGoogle Scholar
  15. 15.
    Lees K, Zivin J, Ashwood TD et al., Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588–600PubMedGoogle Scholar
  16. 16.
    Antithrombotic Trialists‘ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86Google Scholar
  17. 17.
    Algra A, Van Gijn J, Algra A, Koudstaal PJ (1999) Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 66: 557–559PubMedGoogle Scholar
  18. 18.
    Antithrombotic Trialists‘ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists‘ Collaboration. BMJ 308: 81–106Google Scholar
  19. 19.
    Sacco RL, Adams R, Albers G et al. American Heart Association, American Stroke Association Council on Stroke, Council on Cardiovascular Radiology and Intervention, American Academy of Neurology (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37: 577–617PubMedGoogle Scholar
  20. 20.
    Leys D, Kwiecinski H, Bogousslavsky J et al. (2004) Prevention. Cerebrovasc Dis 17: 15–29PubMedGoogle Scholar
  21. 21.
    Solomon SD, Pfeffer MA, McMurray JJ et al. APC and PreSAP Trial Investigators (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028–1035PubMedGoogle Scholar
  22. 22.
    Kearney PM, Baigent C, Godwin J et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308PubMedGoogle Scholar
  23. 23.
    Frelinger AL III, Furman MI, Linden MD et al. (2006) Residual arachidonic acid–induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 113: 2888–2896PubMedGoogle Scholar
  24. 24.
    Chan FK, Ching JY, Hung LC et al. (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244PubMedGoogle Scholar
  25. 25.
    International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 349: 1569–1581Google Scholar
  26. 26.
    CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349: 1641–1649Google Scholar
  27. 27.
    Diener HC, Cunha L, Forbes C et al. (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13PubMedGoogle Scholar
  28. 28.
    ESPRIT Study Group, Halkes PH, Gijn J van et al. (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673Google Scholar
  29. 29.
    CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339Google Scholar
  30. 30.
    Bennett CL, Connors JM, Carwile JM et al. (2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342: 1773–1777PubMedGoogle Scholar
  31. 31.
    Diener HC, Bogousslavsky J, Brass LM et al. MATCH investigators (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337PubMedGoogle Scholar
  32. 32.
    Bhatt DL, Fox KA, Hacke W et al. CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717PubMedGoogle Scholar
  33. 33.
    Batt DL, Flather MD, Hacke W et al. (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49: 1982–1988Google Scholar
  34. 34.
    Kasner SE, Lynn MJ, Chimowitz MI et al., Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators (2006) Warfarin versus aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology 67: 1275–1278PubMedGoogle Scholar
  35. 35.
    Berkefeld J, Hamann GF, Mesnil R du et al. (2006) Endovascular treatment for intracranial stenoses: a common statement by neurologists and neuroradiologists. Nervenarzt 77: 1444–1455PubMedGoogle Scholar
  36. 36.
    ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S, Pogue J et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912Google Scholar
  37. 37.
    Bates SM, Greer IA, Hirsh J, Ginsberg JS (2004) Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 26: 627S–644SGoogle Scholar
  38. 38.
    EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342: 1255–1262Google Scholar
  39. 39.
    Halperin JL for the Executive Steering Committee, SPORTIF III and V Study Investigators (2003) Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146: 431–438PubMedGoogle Scholar
  40. 40.
    Braunwald E, Antman EM, Beasley JW et al. for the American College of Cardiology, American Heart Association, Committee on the Management of Patients With Unstable Angina (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40: 1366–1374PubMedGoogle Scholar
  41. 41.
    Bonow RO, Carabello B, De Leon AC Jr et al. (1998) ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 32: 1486–1588Google Scholar
  42. 42.
    Rodgers A, MacMahon S, Gamble G et al. (1996) Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 313: 147PubMedGoogle Scholar
  43. 43.
    The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153Google Scholar
  44. 44.
    Lawes CMM, Bennett DA, Feigin VL, Rodgers A (2004) Blood pressure and stroke – An overview of published reviews. Stroke 35: 1024–1033PubMedGoogle Scholar
  45. 45.
    Adams HP, Adams RJ, Brott T et al. (2003) Guidelines for the early management of patients with ischemic stroke – A scientific statement from the Stroke Council of the American Stroke Association. Stroke 34: 1056–1083PubMedGoogle Scholar
  46. 46.
    Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists‘ Collaboration. Lancet 362: 1527–1535PubMedGoogle Scholar
  47. 47.
    Gueyffler F, Bulpitt C, Boissel JP et al. (1999) Antihypertensive drugs in very old people. A subgroup meta-analysis of randomised controlled trials. Lancet 353: 793–796Google Scholar
  48. 48.
    Rashid P, Leonardi-Bee J, Bath P (2003) Blood pressure reduction and secondary prevention of stroke and other vascular events – A systematic review. Stroke 34: 2741–2748PubMedGoogle Scholar
  49. 49.
    PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041Google Scholar
  50. 50.
    Chobanian AV, Bakris GL, Black HR et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289: 2560–2572PubMedGoogle Scholar
  51. 51.
    Schrader J, Luders S, Kulschewski A et al. (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1224PubMedGoogle Scholar
  52. 52.
    Wahlgren NG, MacMahon DG, De Keyser J et al. (1994) The Intravenous Nimodipine West European Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 4: 204–210Google Scholar
  53. 53.
    Schrader J, Luders S, Kulschewski A et al. (2003) The ACCESS study-Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703PubMedGoogle Scholar
  54. 54.
    Goldstein LB, Adams R, Alberts MJ et al. American Heart Association/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing, Council; Clinical Cardiology Council; Nutrition; Physical Activity and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group, American Academy of Neurology (2006) Primary prevention of ischemic stroke: a guideline from American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37: 1583–1633PubMedGoogle Scholar
  55. 55.
    Cholesterol Treatment Trialists’ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278Google Scholar
  56. 56.
    Amarenco P, Labreuche J, Lavallée P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902–2909PubMedGoogle Scholar
  57. 57.
    Grundy SM, Cleeman JI, Merz CN et al., Coordinating Committee of the National Cholesterol Education Program (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720–732PubMedGoogle Scholar
  58. 58.
    Amarenco P, Bogousslavsky J, Callahan A et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemnic attack. N Engl J Med 355: 549–559PubMedGoogle Scholar
  59. 59.
    Berge KG, Canner PL (1991) Coronary drug project: experience with niacin. Eur J Clin Pharmacol (Suppl 1) 40: 49–51Google Scholar
  60. 60.
    Brown BG, Zhao X-Q, Alan Chait A et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583–1592PubMedGoogle Scholar
  61. 61.
    Taylor AJ, Sullenberger LE, Lee HJ et al. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–3517PubMedGoogle Scholar
  62. 62.
    Rubins HB, Robins SJ, Collins D et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410–418PubMedGoogle Scholar
  63. 63.
    Ballantyne CM, Lipka LJ, Sager PT et al. (2004) Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 58: 653–658PubMedGoogle Scholar
  64. 64.
    Brousseau ME, Schäfer EJ, Wolfe ML (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505–1515PubMedGoogle Scholar
  65. 65.
    Tanne JH (2006) Pfizer stops clinical trials of heart drug. BMJ 333: 1237PubMedGoogle Scholar
  66. 66.
    Steffen LM, Jacobs DR, Stevens J et al. (2003) Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 78: 383–390PubMedGoogle Scholar
  67. 67.
    Joshipura KJ, Ascherio A, Manson JE et al. (1999) Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 282: 1233–1239PubMedGoogle Scholar
  68. 68.
    Sacks FM, Svetkey LP, Vollmer WM et al. (2001) Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344: 3–10PubMedGoogle Scholar
  69. 69.
    Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553PubMedGoogle Scholar
  70. 70.
    Cleeman JI, Grundy SM, Becker D et al. (2001) Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486–2497Google Scholar
  71. 71.
    Alberti KGMM, Zimmet P, Shaw J (2005) The metabolic syndrome – a new worldwide definition. Lancet 366: 1059–1062PubMedGoogle Scholar
  72. 72.
    Isomaa B, Almgren P, Tuomi T et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683–689PubMedGoogle Scholar
  73. 73.
    Iglseder B, Cip P, Malaimare L et al. (2005) The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke 36: 1212–1217PubMedGoogle Scholar
  74. 74.
    Kernan WN, Inzucchi SE, Viscoli CM et al. (2002) Insulin resistance and risk for stroke. Neurology 59: 809–815PubMedGoogle Scholar
  75. 75.
    Patel PN, Pathak R (2007) Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 64: 481–489PubMedGoogle Scholar
  76. 76.
    Tanne D, Haim M, Goldbourt U et al. (2003) Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 34: 632–636PubMedGoogle Scholar
  77. 77.
    Giles WH, Croft JB, Greenlund KJ et al. (1998) Total homocyst(e)ine concentration and the likelihood of nonfatal stroke – Results from the Third National Health and Nutrition Examination Survey, 1988–1994. Stroke 29: 2473–2477PubMedGoogle Scholar
  78. 78.
    Toole JF, Malinow MR, Chambless LE (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565–575PubMedGoogle Scholar
  79. 79.
    Bonaa KH, Njolstad I, Ueland PM et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578–1588PubMedGoogle Scholar
  80. 80.
    Lonn E, Yusuf S, Arnold MJ et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567–1577PubMedGoogle Scholar
  81. 81.
    North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325: 445–453CrossRefGoogle Scholar
  82. 82.
    European Carotid Surgery Trialists‘ Collaborative Group (1991) MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet 337: 1235–1243Google Scholar
  83. 83.
    MRC European Carotid Surgery Trial (ECST) (1998) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351: 1379–1387Google Scholar
  84. 84.
    Mayberg MR, Wilson SE, Yatsu F et al. (1991) Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis: Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 266: 3289–3294PubMedGoogle Scholar
  85. 85.
    Rothwell PM, Eliasziw M, Fox AJ et al. for the Carotid Endarterectomy Trialists‘ Collaboration (2003) Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361: 107–116PubMedGoogle Scholar
  86. 86.
    Rothwell PM, Eliasziw W, Gutnikov SA et al. for the Carotid Endarterectomy Trialists Collaboration (2004) Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363: 915–924PubMedGoogle Scholar
  87. 87.
    Nicolaides AN, Shifrin EG, Bradbury A et al. (1996) Angiographic and duplex grading of internal carotid stenosis: Can we overcome the confusion? J Endovasc Surg 3: 158–165PubMedGoogle Scholar
  88. 88.
    De Bray JM, Glatt B (1995) Quantification of atheromatous stenosis in the extracranial internal carotid artery. Cerebrovasc Dis 5: 414–426Google Scholar
  89. 89.
    Rantner B, Pavelka M, Posch L et al. (2005) Carotid endarterectomy after ischemic stroke – is there a justification for delayed surgery? Eur J Vasc Endovasc Surg 30: 36–40PubMedGoogle Scholar
  90. 90.
    Lovett JK, Coull AJ, Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62: 569–573PubMedGoogle Scholar
  91. 91.
    Blaser T, Hofmann K, Buerger T et al. (2002) Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe carotid stenosis. Stroke 33: 1057–1062PubMedGoogle Scholar
  92. 92.
    Gasecki AP, Eliasziw M, Ferguson GG et al. (1995) Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. J Neurosurg 83: 778–782PubMedCrossRefGoogle Scholar
  93. 93.
    The SPACE Collaborative Group (2006) 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368: 1239–1247Google Scholar
  94. 94.
    Kern R, Ringleb PA, Hacke W et al. (2007) Stenting for carotid artery stenosis. Nat Clin Pract Neurol 3: 212–220PubMedGoogle Scholar
  95. 95.
    Jean-Louis Mas JL, Chatellier G, Beyssen B et al. (2006) Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355: 1660–1671Google Scholar
  96. 96.
    Executive Committee for the Asymptomatic Carotid Atherosclerosis Study (1995) Endarterectomy for asymptomatic carotid artery stenosis. JAMA 273: 1421–1428Google Scholar
  97. 97.
    Halliday A, Mansfield A, Marro J et al. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group (2004) Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363: 1491–1502PubMedGoogle Scholar
  98. 98.
    Chaturvedi S, Bruno A, Feasby T et al. (2005) Carotid endarterectomy – an evidence-based review. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 65: 794–801PubMedGoogle Scholar
  99. 99.
    Overell JR, Bone I, Lees KR (2000) Interatrial septal abnormalities and stroke: a metaanalysis of case control studies. Neurology 55: 1172–1179PubMedGoogle Scholar
  100. 100.
    Meissner I, Khandheria BK, Heit JA et al. (2006) Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 47: 440–445PubMedGoogle Scholar
  101. 101.
    Agmon Y, Khandheria BK, Meissner I et al. (1999) Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 99: 1942–1924PubMedGoogle Scholar
  102. 102.
    Mas JL, Arquizan C, Lamy C et al. (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345: 1740–1746PubMedGoogle Scholar
  103. 103.
    Santamarina E, Gonzalez-Alujas MT, Munoz V et al. (2006) Stroke patients with cardiac atrial septal abnormalities: differential infarct patterns on DWI. J Neuroimaging 16: 334–340PubMedCrossRefGoogle Scholar
  104. 104.
    Homma S, Sacco RL, DiTullio MR et al. (2002) Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation 105: 2625–2631PubMedGoogle Scholar
  105. 105.
    Messe S, Siverman I, Kizer J et al. (2004) Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 62: 1042–1050PubMedGoogle Scholar
  106. 106.
    The Internet Stroke Center web site. Stroke trials directory. Trial PC: patent foramen ovale and cryptogenic embolism; http://www.strokecenter.org/trials/TrialDetail.aspx?tid=522Google Scholar
  107. 107.
    Khairy P, O’Donnell CP, Landzberg MJ (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systemic review. Ann Intern Med 139: 753–760PubMedGoogle Scholar
  108. 108.
    Diener HC, Allenberg J-R, Bode C et al. (2005) Leitlinie Primär- und Sekundärprävention der zerebralen Ischämie. Herausgegeben von der Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfall-Gesellschaft (DSG). Thieme, Stuttgart oder AWMF online (Nr. 030/075): http://leitlinien.netGoogle Scholar
  109. 109.
    SPREAD, Stroke Prevention and Educational Awareness Diffusion (2003) Italian guidelines for stroke prevention and management: syntheses and recommendations. Milan, ItalyGoogle Scholar
  110. 110.
    U.S. Food and Drug Administration (FDA) Information for Physicians and Patients on the Withdrawal of Two Humanitarian Device Exemptions (HDEs) For Patent Foramen Ovale (PFO) Occluders; http://www.fda.gov/cdrh/ode/h000007-h990011withdraw.htmlGoogle Scholar
  111. 111.
    TACET–The Austrian paradoxical Cerebral Embolism Trial; http://www.meduni-graz.at/neurologie/TACET/Home.htmGoogle Scholar
  112. 112.
    Erkinjuntti T (1999) Cerebrovascular dementia: pathopysiology, diagnosis and treatment. CNS. Drugs 12: 35–48Google Scholar
  113. 113.
    Romàn GC, Erkinjuntti T, Wallin A et al. (2002) Subcortical ischaemic vascular dementia. Lancet Neurol 1: 426–436PubMedGoogle Scholar
  114. 114.
    Zekry D, Hauw JJ, Gold G (2002) Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc 50: 1431–1438PubMedGoogle Scholar
  115. 115.
    Forette F, Seux ML, Staessen JA et al. (2002) The prevention of dementia with treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Intern Med 162: 2046–2052PubMedGoogle Scholar
  116. 116.
    Black S, Romàn GC, Geldmacher DS et al. Donepezil 307 Vascular Dementia Study Group (2003) Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34: 2323–2332PubMedGoogle Scholar
  117. 117.
    Wilkinson D, Doody R, Helme R et al. Donepezil 308 Study Group (2003) Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61: 479–486PubMedGoogle Scholar
  118. 118.
    Erkinjuntti T, Kurz A, Gauthier S et al. (2002) Efficacy of galantamine in probable vascular dementa and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 359: 1283–1290PubMedGoogle Scholar
  119. 119.
    Moretti R, Torre P, Antonello RM et al. (2002) Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 203: 141–146PubMedGoogle Scholar
  120. 120.
    Orgogozo J-M, Rigaud A-S, Stöffler A et al. (2002) Efficacy and safety of menantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33: 1834–1839PubMedGoogle Scholar
  121. 121.
    Wilcock G, Mörbius HJ, Stöffler A; MMM 500 group (2002) A double-blind, placebo controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17: 297–305PubMedGoogle Scholar
  122. 122.
    Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for intracerebral hemorrhage in the general population. A systematic review. Stroke 34: 2060–2066PubMedGoogle Scholar
  123. 123.
    Ferro JM (2006) Update on intracerebral haemorrhage. J Neurol 253: 985–999PubMedGoogle Scholar
  124. 124.
    Roob G, Lechner A, Schmidt R et al. (2000) Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. Stroke 31: 2665–2669PubMedGoogle Scholar
  125. 125.
    Jeong SW, Jung KH, Chu K et al. (2004) Clinical and radiologic differences between primary intracerebral hemorrhage with and without microbleeds on gradient-echo magnetic resonance images. Arch Neurol 61: 905–906PubMedGoogle Scholar
  126. 126.
    Davis SM, Broderick J, Hennerici M et al. (2006) Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66: 1175–1181PubMedGoogle Scholar
  127. 127.
    Willmot M, Leonardi-Bee J, Bath PM (2004) High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 43: 18–24PubMedGoogle Scholar
  128. 128.
    Rochs A, Michelet P, Jullien AC et al. (2004) Longterm outcome in intensive care unit survivors after mechanical ventilation for intracerebral hemorrhage. Crit Care Med 31: 2651–2656Google Scholar
  129. 129.
    Mayer SA, Brun NC, Begtrup K et al., Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352: 777–785PubMedGoogle Scholar
  130. 130.
    Mendelow AD, Gregson BA, Fernandes HM et al., STICH Investigators (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial. Lancet 365: 387–397PubMedGoogle Scholar
  131. 131.
    Engelhard HH, Andrews CO, Slavin KV, Charbel FT (2003) Current management of intraventricular hemorrhage. Surg Neurol 60: 15–22PubMedGoogle Scholar
  132. 132.
    Naff NJ, Carhuapoma JR, Williams MA et al. (2000) Treatment of intraventricular hemorrhage with urokinase. Effect on 30-day survival. Stroke 31: 841–847PubMedGoogle Scholar
  133. 133.
    Naff NJ, Hanley DF, Keyl PM et al. (2004) Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 54: 577–584PubMedGoogle Scholar
  134. 134.
    Maramattom BV, Weigand S, Reinalda M et al. (2006) Pulmonary complications after intracerebral hemorrhage. Neurocrit Care 5: 115–119PubMedGoogle Scholar
  135. 135.
    Delgado P, Alvarez Sabin J, Santamarina E et al. (2006) Plasma S100 B level after acute spontaneous intracerebral hemorrhage. Stroke 37: 2837–2839PubMedGoogle Scholar
  136. 136.
    Hornig CR, Rust DS, Busse O et al. (1994) Space-occupying cerebellar infarction. Clinical course and prognosis. Stroke 25: 372–374PubMedGoogle Scholar
  137. 137.
    Vahedi K, Hofmeijer J, Juettler E et al., DECIMAL, DESTINY, and HAMLET investigators (2007) Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6: 215–222PubMedGoogle Scholar
  138. 138.
    Uhl E, Kreth FW, Elias B et al. (2004) Outcome and prognostic factors of hemicraniectomy for space occupying cerebral infarction. J Neurol Neurosurg Psychiatry 75: 270–274PubMedGoogle Scholar
  139. 139.
    Aichner FT (2003) Diagnostik des Schlaganfalls – ein Update. WMW 153: 14–20PubMedGoogle Scholar
  140. 140.
    Brainin M, Olsen TS, Chamorro A et al., EUSI Executive Committee: EUSI Writing Committee (2004) Organization of stroke care: education, referral, emergency management and imaging, stroke units and rehabilitation. European Stroke Initiative. Cerebrovasc Dis (Suppl 2) 17: 1–14Google Scholar
  141. 141.
    Diener HC et al. (2005) Ischämischer Schlaganfall: Akuttherapie. Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart, S 176–191Google Scholar
  142. 142.
    Latchaw RE, Yonas H, Hunter GJ et al., Council on Cardiovascular Radiology of the American Heart Association (2003) Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association.. Stroke 34: 1084–1104PubMedGoogle Scholar
  143. 143.
    Masdeu JC, Irimia P, Asenbaum S et al. EFNS (2006) EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force. Eur J Neurol 13: 1271–1283PubMedGoogle Scholar
  144. 144.
    Brainin M, Barnes M, Baron JC et al. Guideline Standards Subcommittee of the EFNS Scientific Committee (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces–revised recommendations 2004. Eur J Neurol 11: 577–581PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  • J. Willeit
    • 1
  • S.  Kiechl
    • 1
  • F. Aichner
    • 2
  • K. Berek
    • 3
  • H. Binder
    • 4
  • M. Brainin
    • 5
    • 6
  • F. Fazekas
    • 7
  • G. Fraedrich
    • 8
  • H.P. Haring
    • 2
  • S. Horner
    • 7
  • B. Iglseder
    • 9
  • P. Kapeller
    • 10
  • W. Lang
    • 11
  • E. Minar
    • 12
  • K. Niederkorn
    • 7
  • G. Noisternig
    • 13
  • M. Schillinger
    • 14
  • R. Schmidt
    • 7
  • E. Schmutzhard
    • 1
  • P. Waldenberger
    • 15
  • H.W. Wege
    • 16
  1. 1.Univ.-Klinik für NeurologieMedizinische Universität InnsbruckInnsbruckÖsterreich
  2. 2.Neurologische AbteilungLandesnervenklinik Wagner-JaureggLinzÖsterreich
  3. 3.Abteilung für NeurologieKrankenhaus KufsteinKufsteinÖsterreich
  4. 4.Neurologisches Zentrum Rothschildstiftung Maria-Theresien-SchlösselWienÖsterreich
  5. 5.Klinische NeurowissenschaftenDonau-Universität KremsKremsÖsterreich
  6. 6.Abteilung NeurologieLandesklinikum Donauregion TullnTullnÖsterreich
  7. 7.Univ.-Klinik für NeurologieMedizinische Universität GrazGrazÖsterreich
  8. 8.Univ.-Klinik für GefässchirurgieMedizinische Universität InnsbruckInnsbruckÖsterreich
  9. 9.Univ.-Klinik für GeriatrieChristian-Doppler-KlinikSalzburgÖsterreich
  10. 10.Abteilung für NeurologieLandeskrankenhauses VillachVillachÖsterreich
  11. 11.Neurologische AbteilungKrankenhaus der Barmherzigen BrüderWienÖsterreich
  12. 12.Univ.-Klinik für Innere Medizin, Abteilung für AngiologieMedizinische Universität WienWienÖsterreich
  13. 13.Abteilung für NeurologieLandeskrankenhaus KlagenfurtKlagenfurtÖsterreich
  14. 14.Abteilung für KardiologieWilhelminenspitalWienÖsterreich
  15. 15.Radiologische AbteilungKrankenhaus der Barmherzigen SchwesternLinzÖsterreich
  16. 16.Neurologische AbteilungLandesnervenklinik Sigmund FreudGrazÖsterreich

Personalised recommendations